Biomarkers to Predict Cancer Therapy-related Cardiotoxicity
Recruiting now
Conditions studied: Hematopoietic and Lymphatic System Neoplasm, Malignant Solid Neoplasm
In brief
This study evaluates why some cancer patients but not others experience changes in heart function following treatment with chemotherapy.
Key facts
- Study ID
- NCT06353191
- Run by
- Mayo Clinic
- People needed
- 693
- Starts
- 2019-05-03
- Expected to finish
- 2031-12-31
- Last updated by the study team
- 2026-08-06
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- 18 years of age or older
- Treated for any malignancy with any type of chemotherapy including oral, parenteral therapy and immunotherapy
- One of the following:
- Diagnosed with cardiotoxicity defined as; cardiomyopathy, symptomatic heart failure, asymptomatic reduced systolic function, acute coronary syndrome, myocardial infarction, critical limb ischemia, cardiac arrhythmias or myocarditis possibly related to prior cancer treatment
- Completed chemotherapy with no cardiotoxicity at least two years post treatment
- Patients with cancer who will be initiating systemic therapy with potentially cardiotoxic medications. This will include chemotherapy, immunotherapy, targeted therapy that have been associated with cardiac toxicity
- An understanding of the protocol and its requirements, risks, and discomforts
- The ability and willingness to sign an informed consent
You may not qualify if…
- Inability on the part of the patient to understand the informed consent or be compliant with the protocol
Where it is running
- Mayo Clinic in Arizona — Scottsdale, Arizona, United States (enrolling)
- Mayo Clinic in Florida — Jacksonville, Florida, United States (enrolling)
- Moffitt Cancer Center — Tampa, Florida, United States (enrolling)
- Mayo Clinic in Rochester — Rochester, Minnesota, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.